Main content

    Esophageal / Gastrointestinal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Description: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older, who have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma of the gastrointestinal (GI) tract
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: about Study EA2142

    Title: Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments
    Description: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with a histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction and who have previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: about Study Taiho 302

    • updated February 2016

    Back to top